Eli Lilly has entered into a definitive agreement to acquire Kelonia Therapeutics, a biotechnology firm focused on next-generation cell therapies, in a transaction that could be worth as much as $7 billion. The deal, announced on Monday, April 20, 2026, marks a significant expansion of Lilly's oncology portfolio as the pharmaceutical giant seeks growth avenues beyond its blockbuster obesity and diabetes franchises.
Under the terms, Kelonia shareholders will receive $3.25 billion upfront, with an additional $3.75 billion contingent upon the achievement of future clinical, regulatory, and commercial milestones. The acquisition price substantially exceeds earlier reports that suggested a deal valued at over $2 billion. Following the announcement, shares of Eli Lilly traded approximately 2.5% higher in morning trading.
Strategic Shift Beyond Metabolic Drugs
The move is part of a concerted strategic effort by Lilly to diversify its revenue sources. In 2025, the company's metabolic drugs delivered staggering sales: Mounjaro generated $23.0 billion and Zepbound added $13.5 billion, contributing to a 45% surge in total revenue to $65.2 billion. Its cancer drug Verzenio also posted strong results with $5.7 billion in sales.
Kelonia represents the latest in a series of strategic acquisitions for Lilly in 2026, following deals for Orna Therapeutics, Ventyx Biosciences, and Centessa Pharmaceuticals. This buying spree underscores the company's commitment to building a robust pipeline of new growth drivers outside its core metabolic disease business.
The Promise of In-Body CAR-T
At the heart of the acquisition is Kelonia's lead candidate, KLN-1010, currently in Phase 1 clinical trials for relapsed or refractory multiple myeloma. This blood cancer affects patients whose disease has returned or stopped responding to prior treatments.
KLN-1010 is built on Kelonia's proprietary iGPS platform, which is designed to create chimeric antigen receptor T-cell (CAR-T) therapy inside the patient's body. This in vivo approach aims to circumvent the complex, costly, and time-consuming traditional CAR-T manufacturing process, which involves extracting a patient's T cells, genetically engineering them in a laboratory, and then reinfusing them.
Jacob Van Naarden, head of Lilly's oncology division, highlighted the potential of the technology, noting that current CAR-T treatments still face significant manufacturing, safety, and access hurdles. He characterized early data for KLN-1010 as "highly encouraging." Kevin Friedman, Kelonia's Chief Executive, stated the company had observed "deep multiple myeloma remissions" with its approach, which offers reduced complexity and cost compared to conventional ex vivo CAR-T methods.
Market Context and Competitive Landscape
The acquisition positions Lilly more directly in the competitive multiple myeloma cell therapy market, where Johnson & Johnson's Carvykti and Bristol Myers Squibb's Abecma are already approved in the United States. Lilly already maintains a substantial cancer business through Verzenio and recently secured an expanded U.S. label for Jaypirca in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Early data for KLN-1010, presented at the 2025 American Society of Hematology meeting, showed promising tolerability. However, the investment carries inherent risk, as the lead program has not advanced beyond Phase 1 testing. Commenting on Lilly's earlier acquisition of Orna Therapeutics, BMO Capital Markets analyst Evan Seigerman described the broader in vivo cell-therapy technology as "high-risk" until validated in larger clinical trials.
Furthermore, approved CAR-T medicines remain under FDA surveillance for serious toxicities, even after the agency removed a special safety program known as REMS last year. The transaction is expected to close in the second half of 2026, pending regulatory approvals and other customary closing conditions.
